Introduction Since their introduction, drug-eluting stents (DES) have revolutionized percutaneous treatment of coronary artery disease with rates of in-stent restenosis of between 2 and 10% [] and ...

A “bioadaptive” stent might circumvent the slow accumulation of target lesion failure that has been a consistent weakness of ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

Abbott (NYSE:ABT) today announced data demonstrating the long-term effectiveness of its Esprit BTK drug-eluting stent.

Abbott has delivered new, longer-term data from a clinical study of its dissolving stent for severe peripheral artery disease ...

More recently, drug-eluting stents (DESs) have emerged as the predominant percutaneous strategy in patients with coronary artery disease. This Review summarizes the knowledge on coronary stenting ...

The ELEGANCE registry, which is focused on historically underrepresented minorities and women, analyzed endovascular treatment ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

For percutaneous coronary intervention (PCI) on de novo lesions, the DynamX bioadaptor not only matched drug-eluting stents ...

You’ll usually need to continue dual antiplatelet drug therapy for a year after a drug-eluting stent placement and a month after a bare-metal stent placement. Drug-eluting stents are a newer ...

Non-drug eluting devices, such as bare-metal stents, catheters, and implantable medical devices, are widely used in procedures where drug elution is not necessary, or where a more mechanical or ...

Non-drug eluting devices, such as bare-metal stents, catheters, and implantable medical devices, are widely used in procedures where drug elution is not necessary, or where a more mechanical or ...